TRAIL-R2 and HER2 Bi-Specific CAR T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TRAIL-R2 and HER2 Bi-Specific CAR T Cells, covering 2026-03-04 to 2026-03-04. Get the full timeline:
Most recent: Clinical Trial Update: TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer [Phase 1]